Mebendazole
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed High-Grade Glioma
Conditions
Newly Diagnosed High-Grade Glioma
Trial Timeline
Apr 4, 2013 → Apr 16, 2021
NCT ID
NCT01729260About Mebendazole
Mebendazole is a phase 1 stage product being developed by Brain Biotech for Newly Diagnosed High-Grade Glioma. The current trial status is completed. This product is registered under clinical trial identifier NCT01729260. Target conditions include Newly Diagnosed High-Grade Glioma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01729260 | Phase 1 | Completed |
Competing Products
18 competing products in Newly Diagnosed High-Grade Glioma